慢性胃炎 中国就医指南

Chronic gastritis is a persistent, long-term inflammatory condition of the gastric mucosa, characterized by histological evidence of chronic inflammatory cell infiltration—primarily lymphocytes and plasma cells—often accompanied by glandular atrophy, intestinal metaplasia, or dysplasia in advanced cases. Unlike acute gastritis, which presents with sudden, transient symptoms, chronic gastritis develops insidiously over months to years and may remain asymptomatic for extended periods. Its pathogenesis is multifactorial: Helicobacter pylori infection accounts for approximately 80–90% of cases globally and triggers sustained immune-mediated mucosal injury through virulence factors (e.g., CagA, VacA) and host genetic susceptibility. Other key mechanisms include autoimmune gastritis (targeting parietal cells and intrinsic factor, leading to pernicious anemia), long-term use of NSAIDs or aspirin (disrupting prostaglandin-mediated mucosal defense), bile reflux, chronic alcohol consumption, smoking, and systemic conditions such as Crohn’s disease or sarcoidosis. Epidemiologically, chronic gastritis affects an estimated 50% of the global adult population, with prevalence rising sharply with age—reaching 70–80% in individuals over 60 years. H. pylori seroprevalence remains particularly high in low- and middle-income countries (>70%), while autoimmune and NSAID-related subtypes predominate in Western aging populations. Major modifiable risk factors include untreated H. pylori infection, habitual NSAID use, smoking, excessive alcohol intake, poor dietary habits (e.g., high-salt, smoked, or nitrate-rich foods), and chronic psychological stress. Non-modifiable risks include older age, female sex (for autoimmune gastritis), and genetic polymorphisms in IL-1β and TNF-α genes. Although many patients are asymptomatic, symptomatic individuals commonly report nonspecific upper gastrointestinal complaints—including postprandial epigastric discomfort, early satiety, nausea, bloating, and occasional anorexia. Importantly, chronic gastritis significantly impacts quality of life: longitudinal studies show reduced physical functioning, increased anxiety and depression scores, impaired work productivity, and diminished social engagement—particularly among those with persistent symptoms or complications like iron-deficiency anemia or vitamin B12 deficiency. In a subset of patients, especially those with atrophic gastritis and intestinal metaplasia, there is an elevated risk of gastric adenocarcinoma (up to 6-fold higher over 10–20 years), underscoring the importance of endoscopic surveillance in high-risk groups. Early diagnosis via upper endoscopy with targeted biopsies—and accurate histopathological classification using the Updated Sydney System—is essential for risk stratification and personalized management.

# 慢性胃炎治疗方案与费用明细（消化内科）

一、非手术保守治疗（适用绝大多数患者）

• •基础方案：生活方式干预+抑酸+护膜+根除幽门螺杆菌（如阳性）

- 幽门螺杆菌检测（C13呼气试验）：220–320元 - 四联根除方案（14天）：药物费480–1,200元（国产/进口质子泵抑制剂+两种抗生素+铋剂）

• •中重度伴糜烂/肠化生者：加用胃黏膜保护剂（替普瑞酮等），月均药费300–900元

二、内镜下介入治疗（限特殊并发症）

• •适用条件：慢性胃炎合并持续性出血、重度萎缩伴高级别上皮内瘤变（需病理确诊）
• •方案：内镜下氩离子凝固术（APC）或高频电凝止血

- 内镜治疗费（含麻醉）：2,800–4,500元

三、复杂/耐药/癌前病变方案

• •幽门螺杆菌多次根除失败：行药敏检测（胃黏膜细菌培养+基因测序）：1,200–2,000元；个体化三联/序贯方案药费1,500–3,000元/疗程
• •重度肠化/异型增生：每6–12个月定期内镜随访（年均费用约1,200–2,000元）

方案快速选择指南

✅ 初诊轻症/预算有限：选基础保守治疗（总启动成本≤2,500元） ✅ Hp阳性/反复复发：四联根除+3个月维持护膜（总费用约3,500–5,000元） ✅ 病理提示癌前病变：立即启动内镜监测+专科随访（首年投入约6,000–8,500元）